ライフサイエンスコーパス: drug targeting

1 dicting the suitability of each molecule for drug targeting.

2 r poor availability are major bottlenecks in drug targeting.

3 peptides as vehicles for hepatocyte-specific drug targeting.

4 oter G-quadruplex loop isomers and for their drug targeting.

5 understanding of their biological roles and drug targeting.

6 gene candidates for mutational analysis and drug targeting.

7 , and may provide specific binding sites for drug targeting.

8 abolism and providing an additional site for drug targeting.

9 iers, suggesting opportunities for selective drug targeting.

10 sent a rational subset of family members for drug targeting.

11 higher dose of free MP, possibly by means of drug targeting.

12 ing sites remain conserved and available for drug targeting.

13 re are in driver genes or genes amenable for drug targeting.

14 at sustain cancer cells and are suitable for drug targeting.

15 cular due to their potential applications in drug targeting.

16 10, IL-18, and IL-12 p40, and identified 140 drugs targeting 16 of them.

17 small (+)RNA virus, to brefeldin A (BFA), a drug targeting a cellular component of the viral replica

18 The only marketed drug targeting a PAR is vorapaxar, a selective antagonis

19 patterns of gene response that indicate that drugs targeting a particular gene will be likely or not

20 llular responses, opening the possibility of drugs targeting a receptor subtype in specific brain reg

21 It is our opinion that those promoting drugs targeting a single or few molecules should not red

22 or optimal development and implementation of drugs targeting aberrant AKT activation.

23 mportant implications for the development of drugs targeting Abeta production in Alzheimer disease.

24 al implications for the development of safer drugs targeting Abeta production through gamma-secretase

25 oma, with direct implications for the use of drugs targeting acetylation/deacetylation mechanisms.

26 py cancer cells are effectively treated with drugs targeting acquired phenotypes.

27 s are beginning to provide novel avenues for drug targeting against infectious agents.

28 at laquinimod may represent a first-in-class drug targeting AhR for the treatment of multiple scleros

29 Drugs targeting AmgRS would thus be expected to enhance

30 iomarkers are used as surrogate measures for drug targeting and approval and are generally based on p

31 a membrane-protein-supporting platform, or a drug targeting and delivery vehicle in general, is under

32 membrane protein functions, or involved with drug targeting and delivery.

33 y emerged as a versatile protein carrier for drug targeting and for improving the pharmacokinetic pro

34 e sugar component(s) to provide benefits for drug targeting and stimuli responsive systems.

35 delivery, cancer stem cell therapy, magnetic drug targeting and ultrasound-mediated drug delivery, ha

36 therefore, offers an attractive paradigm for drug targeting and, consequently, the delineation of the

37 have potential utility both as an anticancer drug targeting ANG and as a tool for the investigation o

38 Drugs targeting angiogenesis are rapidly being incorpora

39 m is simple to operate and multiplex to test drugs targeting angiogenesis in a more physiologically r

40 s for the promising therapeutic potential of drugs targeting Annexin-1.

41 volanesorsen, a second-generation antisense drug targeting apoC-III, were determined in 2 human inte

42 eveloping, testing, and ultimately improving drugs targeting AR.

43 oped principles of size-dependent lymph node drug targeting are conserved in melanomas, suggesting th

44 Drugs targeting astrocyte signaling have a potential ben

45 icle (VLP) vaccine as well as small-molecule drugs targeting astrovirus assembly/maturation.

46 t of a VLP vaccine as well as small-molecule drugs targeting astrovirus assembly/maturation.

47 de the development of vaccines and antiviral drugs targeting astrovirus.

48 on way to evaluate the therapeutic effect of drugs targeting atherosclerosis because of an inherent d

49 fute the start of a large-scale M&M trial on drugs targeting atherosclerosis.

50 hibitor JQ1 combined favorably with multiple drugs targeting B-cell receptor signaling, one pathway t

51 ates a proof of concept for tissue-selective drug targeting based on G protein-coupled receptor heter

52 These data imply an efficacy of drugs targeting BAT to treat metabolic disease that is a

53 therapies may profit from combinations with drugs targeting BCR(-) tumour cells.

54 Therefore, drugs targeting beta-chemokines (CCL2 and CCL22), FGF-ba

55 ss of molecules used to engineer adhesion in drug targeting, biosensing, self-assembling nanostructur

56 Drugs targeting BK channel represent a potential therape

57 ly suitable for the development of antiviral drugs targeting both influenza A and B viruses.

58 Thus, drugs targeting both WT and the S31N mutant are highly d

59 These ELP(BC)'s may be useful for drug targeting by thermally triggered multivalency.

60 Drugs targeting calcineurin are potent antifungal agents

61 ty for the development and implementation of drugs targeting cell metabolism and aberrant AKT signali

62 d medicines targeting specific mutations and drugs targeting cellular pathways to gene-based and cell

63 s of this channel and the development of new drugs targeting cellular proton transport.

64 reduces CSD, supporting the possible use of drugs targeting central CGRP receptors as antimigraine a

65 (RO) of MK-0249 and MK-3134, 2 potential IA drugs targeting cerebral H3 receptors, in 6 healthy male

66 Further investigation of drugs targeting chromatin regulators is warranted in HPV

67 accelerate the development of new antiviral drugs targeting cis-acting RNA regulatory signals.

68 s development of combination treatments with drugs targeting compensatory pathways, will be key to ac

69 insight into the development of novel cancer drugs targeting control of intracellular free zinc and t

70 some properties in the "rule of five", while drugs targeting cytochrome P450s, biogenic amine GPCRs,

71 However, clinically approved drugs targeting D2 DAR display poor selectivity between

72 en together, the data support the utility of drugs targeting D3/D4 receptors as potential treatments

73 The application of drugs targeting different convulsant mechanisms (4-Amino

74 Effects of different drugs, targeting different parts of the Boolean circuit,

75 rs of PKR should be used in combination with drugs targeting directly the inflammasome.

76 nal nanomaterials and the design of anti-HIV drugs targeting (dis)assembly and biocompatible nanocoat

77 elopment of diagnostic tools and therapeutic drugs targeting disease-causing RNAs.

78 d to TSase, which may lead to a new class of drugs targeting DNA biosynthesis.

79 ncrease the efficiency of several anticancer drugs targeting DNA.

80 ponse (EHR), hold promise for developing new drugs targeting dormancy phase MTB.

81 potential therapeutic and adverse effects of drugs targeting DRN neurons.

82 e logical postulation that intervention with drugs targeting dysregulated glial proinflammatory cytok

83 eases, as well as facilitating the design of drugs targeting EBV BILF1.

84 FLIM-FRET) Src biosensor was used to monitor drug-targeting efficacy in a transgenic p53-mutant mouse

85 d that this can be used to map areas of poor drug-targeting efficiency within specific tumor microenv

86 ime point and serve as hypotheses for future drug targeting efforts specific to the stages of disease

87 Several drugs targeting EGFR activity are approved cancer therap

88 ly central to psoriasis pathogenesis because drugs targeting either cytokine are highly effective tre

89 sivelestat, the only approved small molecule drug targeting elastase, which indicated its potential i

90 These data suggest that drugs targeting endothelial exocytosis may be useful in

91 In contrast, drugs targeting ERalpha (PPT and MPP), GPR30 (G1 and G15

92 gnaling on myofibrillar organization because drugs targeting ERBB2 (HER2/NEU) signaling, a mainstay o

93 These results show that drugs targeting extracellular domains of VEGF receptors

94 Drugs targeting F508del CFTR and premature termination c

95 ents with an inflammatory signature, whereas drugs targeting fibrosis are likely to benefit those wit

96 3-ITD-dependent AML results in resistance to drugs targeting FLT3.

97 ss that uses antibodies to improve cytotoxic drug targeting for cancer treatment.

98 el signaling pathway that may be amenable to drug targeting for clinical applications.

99 5 initiates cancer and demonstrate effective drug targeting for potential therapy of human LGL leukem

100 n of VEGF and are amenable to small molecule drug targeting for VEGF suppression.

101 tentially be exploited therapeutically using drugs targeting GABA(A) receptors.

102 targeting, triggered release, intracellular drug targeting, gene delivery, cancer stem cell therapy,

103 human tumours with greater vulnerability to drugs targeting glycolysis.

104 e exercised in the use of newer, more potent drugs targeting GSK-3 in women of childbearing age.

105 ear rationale for the development and use of drugs targeting GSK-3 to treat diseases such as diabetes

106 Currently, no small-molecule drug targeting GSTO1 is under clinical development.

107 Magnetic drug targeting has been proposed as means of concentrati

108 For example, letermovir is a small-molecule drug targeting HCMV terminase that is currently in phase

109 -animal model for evaluating novel antiviral drugs targeting HCV NS3-NS4A protease and T-cell-based H

110 Drugs targeting HIF-1alpha are being developed, but the

111 This may suggest that as well as drugs targeting histone modifications, it will be valuab

112 nd 9 also inhibited HIV strains resistant to drugs targeting HIV reverse transcriptase, protease, int

113 lecular basis of toxicity of anti-retroviral drugs targeting HIV reverse transcriptase.

114 Statins are cholesterol-lowering drugs, targeting HMG-CoA reductase, thereby reducing the

115 new focus for therapeutic intervention with drugs targeting host signaling mediators rather than vir

116 p in designing a novel class of antileukemia drugs targeting HTLV-1 PR and in predicting their drug-r

117 -promoting pathways in glioblastoma and that drugs targeting Id-1 represent a novel and promising str

118 The success and safety profile of drugs targeting IL -1 in the treatment of CAPS and DIRA

119 and allows for evaluation of investigational drugs targeting IL-6-dependent MM cells in the human bon

120 engineering of ligands, enabling studies of drug targeting in animal species and subsequent use in h

121 F1 may represent an attractive candidate for drug targeting in CRC.

122 drug dispersion with animal models, accurate drug targeting in humans remains a challenge.

123 a partial picture of available receptors for drug targeting in vivo is provided.

124 a purely chemical means to achieve selective drug targeting in vivo.

125 This mechanism has critical implications for drug-targeting in multidrug-resistant tumors where a str

126 flammatory mechanisms could be exploited for drug-targeting in the development of novel agents for CN

127 Drugs targeting individual G protein-coupled receptors a

128 development of personalized therapy for SSc; drugs targeting inflammation are likely to benefit those

129 s selective androgen receptor modulators and drugs targeting inflammatory cytokines that promote skel

130 block anaphylaxis, an important feature for drugs targeting inflammatory disease in general.

131 r shows that raltegravir, the antiretrovirus drug targeting integrase, is effective against various h

132 Eosinophils are suppressed by a new class of drugs targeting Interleukin-5 (IL-5), an eosinophil grow

133 At the same time, conventional antagonist drugs targeting ion channels have yielded poor survival

134 ing these enzymes and as leads for potential drugs targeting JNKs.

135 ves the way for the design of new antibiotic drugs targeting l,d-transpeptidases.

136 provide critical insights for development of drugs targeting LTA4H.

137 est of lesional macrophages, suggesting that drugs targeting macrophage proliferation may be useful i

138 Drugs targeting macrophage TLR8-linked signaling pathway

139 rs influencing mortality; with this in mind, drug-targeting mechanisms involved in liver injury shoul

140 Drugs targeting mechanisms involved in severe malaria pa

141 a process for dissecting the complexities of drug targeting mediated by nanoparticulate carriers.

142 ance of 4-quinolinamines as a novel class of drugs targeting membrane biogenesis via inhibition of PS

143 Drugs targeting metabolism have formed the backbone of t

144 Drugs targeting metabotropic glutamate receptor 5 (mGluR

145 w insights into the mechanisms through which drugs targeting mGlu II receptors alleviate hypoglutamat

146 type expression in the response of tumors to drugs targeting microtubules.

147 We anticipate that rational development of drugs targeting molecular chaperones might help in futur

148 isease that can successfully be treated with drugs targeting mutant onco-proteins has motivated whole

149 le information for future rational design of drugs targeting nAChRs.

150 Development of drugs targeting nephrin may represent a novel approach t

151 Overall, these results suggest that drugs targeting non-alpha7 nicotinic receptors may be us

152 ulation, and to support the discovery of new drugs targeting NRs.

153 cessful proof-of-concept study suggests that drugs targeting NS4B may represent a viable treatment op

154 hese activities should help in the design of drugs targeting nsp1.

155 may also be needed in patients treated with drugs targeting NTCP.

156 Drug targeting of adult stem cells has been proposed as

157 lts suggest a rational strategy for enhanced drug targeting of Bcr-Abl and other multidomain kinase s

158 e essential core of the glideosome, enabling drug targeting of both of its core components to inhibit

159 uence and provide important implications for drug targeting of G-quadruplexes in human telomeres.

160 ort, and offers a potentially novel site for drug targeting of PARG.

161 tudy provides proof of concept for selective drug targeting of proximal tubular cells on the basis of

162 m a multifactorial origin, thus conventional drug targeting of single proteins may not prove most eff

163 Accordingly, any potential drug targeting of this gene product must be strictly ass

164 Selective drug targeting of this osteoblast signaling pathway may

165 rapy, radiation therapy, and, more recently, drugs targeting oncogenes, have earned their place only

166 ligands in innate and acquired resistance to drugs targeting oncogenic kinases.

167 can also be distinguished, and we find that drugs targeting only VEGFRs (Apatinib and Vandetanib) ar

168 door to the rapid development of additional drugs targeting other disease-associated genes in the sa

169 ion, might be used in combination with other drugs targeting other mechanisms of disease, although ad

170 However, promising new drugs targeting other receptors are under investigation.

171 light of recent clinical trials that employ drugs targeting p110delta in certain cancers and other d

172 rombus formation, and several antithrombotic drugs targeting P2Y12R--including the prodrugs clopidogr

173 The data may affect the design of drugs targeting Parp proteins and the improvement of rad

174 iPSC-CMs using tacrolimus and rosiglitazone, drugs targeting pathways predicted to produce cardiotoxi

175 Several drugs targeting PI3K/ATK are currently in clinical trial

176 Few drugs targeting picornaviruses are available, making the

177 should help the design of novel antimalarial drugs targeting Plasmodium sexual stages.

178 Though there are many anti-cancer drugs targeting primary tumor growth, anti-metastatic ag

179 family reveals that molecular properties of drugs targeting proteases, lipid and peptide G-protein-c

180 With the recent clinical success of drugs targeting protein kinase activity, drug discovery

181 al importance and analyze the development of drugs targeting protein phosphatases.

182 s) network, which sensitizes cancer cells to drugs targeting protein quality control (PQC) regulators

183 evant topology is critical for the design of drugs targeting quadruplex nucleic acids.

184 ghts, will be important for the discovery of drugs targeting quadruplexes from particular genes.

185 ercoming the resistance against experimental drugs targeting Ref-1 activity, with clear translational

186 dormancy and may facilitate the discovery of drugs targeting relapsing malaria.

187 Drugs targeting RR are mainly nucleoside in nature.

188 ally available antileukemic and antilymphoma drugs targeting SCD1 have been reported.

189 (2) Resistance to drugs targeting secreted compounds downstream of QS for

190 y distinct 5-HT receptors, could explain why drugs targeting serotonin function can cause either diab

191 be shared between the two genders for a few drugs targeting sex-specific cancers (e.g., PD-0332991 f

192 stment equation away from the development of drugs targeting short course therapies for acute disease

193 and clinical trial testing of several novel drugs targeting specific CFTR mutations.

194 gative proteins, small interfering RNAs, and drugs targeting specific endocytic pathways, we found th

195 opportunities for structure-based design of drugs targeting specific nicotinic acetylcholine recepto

196 "expanded serotonin biology" and discuss how drugs targeting specific serotonin receptors are beginni

197 r-more-sophisticated animal models and newer drug targeting strategies, should promote novel therapeu

198 able controversy on the practical outcome of drug targeting strategies.

199 Drugs targeting subtypes of these receptors have proven

200 Drugs targeting such epigenetic mechanisms may open ther

201 e necessary steps toward achieving efficient drug targeting systems.

202 To identify drugs targeting tau neurotoxicity, we have used a Caenor

203 ndidates for multiplex vaccines and/or novel drugs targeting TEMs in the schistosome tegument.

204 Drug targeting that reverses miR-29b repression cures ot

205 ponse of MCTS following UNC1999 treatment, a drug targeting the enzymes that catalyze H3K27me3, namel

206 tive treatment with etanercept, a biological drug targeting the TNF pathway and suppressing inflammat

207 These results suggest that drugs targeting the 12/15-lipoxygenase pathway merit inv

208 ool would assist in the development of novel drugs targeting the 5-HT6 receptor.

209 disorder, then development of antiangiogenic drugs targeting the abnormal brain endothelial cell migh

210 the way for the development of new selective drugs targeting the amyloidogenic proteins implicated in

211 catastrophic cell division, we reasoned that drugs targeting the checkpoint might provide a therapeut

212 ke inhibitors are the most widely prescribed drugs targeting the CNS with acute and chronic effects i

213 Whether novel drugs targeting the constitutively active JAK2/STAT path

214 be considered in the clinical development of drugs targeting the cytochrome bc1 :aa3 , as well as for

215 paired, and which are primarily treated with drugs targeting the dopaminergic and serotoninergic syst

216 of vaccine strategies and the development of drugs targeting the early stages of Hepatitis C virus (H

217 nce, great efforts have been made to develop drugs targeting the EET pathway.

218 drugs has distinct properties compared with drugs targeting the endogenous (orthosteric) ligand-bind

219 enza virus in cell culture and suggests that drugs targeting the enzyme complex via these subunits ma

220 Drugs targeting the epigenome are new promising cancer t

221 ovide a template for designing more specific drugs targeting the folate receptor system.

222 Drugs targeting the gamma-secretase nucleotide-binding s

223 eutic exploitation of the next generation of drugs targeting the genetic basis of cancer will require

224 eful in efforts to develop clinically useful drugs targeting the HIV-1 capsid.

225 Selective inhibition is needed for drugs targeting the hypoxanthine phosphoribosyltransfera

226 s for the first time, to our knowledge, that drugs targeting the IKK complex are cardioprotective aga

227 ing that they might be sensitive to emerging drugs targeting the IL-10 pathway.

228 Consequently, drugs targeting the inactive or guanosine 5'-diphosphate

229 izes the interest of novel anti-tuberculosis drugs targeting the initial steps of PIM biosynthesis.

230 alized treatment of affective disorders with drugs targeting the metabotropic glutamate receptor 3.

231 Several drugs targeting the myostatin pathway have been used in

232 garding the safety of chronic application of drugs targeting the Notch pathway, specifically those ta

233 te the effect of treatments with fluorescent drugs targeting the nucleus.

234 t would be useful for evaluation of glaucoma drugs targeting the outflow pathway.

235 resistance to fulvestrant can be overcome by drugs targeting the PI3K pathway.

236 this event was the therapeutic potential of drugs targeting the PI3K/mTOR signaling pathway for the

237 Drugs targeting the PPARgamma pathway might be effective

238 mycin and for the design of novel allosteric drugs targeting the proteasome.

239 Food and Drug Administration (FDA)-approved drugs targeting the related human immunodeficiency virus

240 Development of drugs targeting the ribosome, the site of protein synthe

241 small molecules will be required to discover drugs targeting the root causes of human disease in the

242 The wide range of drugs targeting the serotonergic system could be useful

243 We demonstrate here in silico that drugs targeting the specific RNA-capsid protein contacts

244 malian cell DNA replication, indicating that drugs targeting the terminase complex could be safe and

245 reasons for the delay in this pipeline, the drugs targeting the ubiquitin system that have been deve

246 based rational development of small molecule drugs targeting the VEGF G-quadruplex for gene suppressi

247 aripiprazole, and risperidone, and of kinase drugs targeting the VEGF receptor, demonstrates how unde

248 olon cancer-bearing mice (CT26) treated with drugs targeting the VEGF/VEGFR axis.

249 s the possibility of using clinically tested drugs, targeting the Wnt/beta-catenin pathway, for the n

250 lable antiandrogen drugs, development of new drugs targeting these AR isoforms may potentially be eff

251 f d-FEN's anorexic actions and indicate that drugs targeting these downstream melanocortin pathways m

252 of inhibitors has limited the development of drugs targeting these enzymes.

253 olecular basis for clinically developing new drugs targeting these gene mutations for GIST therapy.

254 Importantly, drugs targeting these GPVI signaling pathways are alread

255 To aid the development of drugs targeting these kinases, it is necessary to expres

256 These data raise the possibility that drugs targeting these kinases, or PI3K itself, might hav

257 Accordingly, drugs targeting these pathological processes in the CNS

258 tant regulators of airway cell function, and drugs targeting these receptors are among the first line

259 iation of MDMA-induced hyperthermia and that drugs targeting these receptors, such as carvedilol, war

260 ition is critical for the rational design of drugs targeting these tissues.

261 cance for the design of novel AD therapeutic drugs targeting this APP domain.

262 ht reveal the pharmacodynamic (PD) effect of drugs targeting this cancer-specific metabolic pathway.

263 is for the development of novel antidiabetic drugs targeting this class of receptors.

264 d the orthosteric binding site, showing that drugs targeting this diverse surface could function as a

265 inherent advantages over currently available drugs targeting this enzyme.

266 model of the T6SS will facilitate design of drugs targeting this highly prevalent secretion apparatu

267 and demonstrate the therapeutic potential of drugs targeting this pathway in the treatment of KS.

268 investigated the effect of immunosuppressive drugs targeting this pathway, the JAK inhibitor tofaciti

269 With the development of many cancer drugs targeting this pathway, there is a need for releva

270 eful in the development of anti-tuberculosis drugs targeting this pathway.

271 may provide novel avenues for the design of drugs targeting this receptor.

272 that supports virus production suggests that drugs targeting this region of the enzyme will still be

273 e responsible for parasite transmission, and drugs targeting this stage are needed to support malaria

274 nd thus the potential efficacy of envisioned drugs targeting this tissue to treat metabolic disease.

275 Drug targeting those networks, in combination with BRAF

276 as new lead compounds for the development of drugs targeting TLR4 activation and signaling in infecti

277 e spectrum of systems affected by TNF alpha, drugs targeting TNF alpha have a potential risk of delay

278 Drug targeting to a highly expressed, noninternalizable

279 Drug delivery systems are required for drug targeting to avoid adverse effects associated with

280 Drug targeting to cellular receptors involved in endocyt

281 al as a means of enhancing immunotherapy via drug targeting to lymphocytes and lymph nodes.

282 corporated in Sap inhibitors for Candidiasis drugs targeting to lysosomes.

283 tdp1 mutations can sensitize yeast cells to drugs targeting Top2 even when TOP1 is deleted.

284 In addition, side effects of anticancer drugs targeting TOP2A could result from inhibition of TO

285 a new model for understanding the action of drugs targeting topoisomerase II.

286 ons for the development of anti-inflammatory drugs targeting TPL-2.

287 Several novel drugs targeting TRAIL receptors are currently in clinica

288 It remains unclear to what extent drugs targeting transcriptional repressor complexes affe

289 Drugs targeting two previously discovered painlessness g

290 We also discuss the therapeutic potential of drugs targeting various aspects of tau biology.

291 Several drugs targeting vascular endothelial growth factor (VEGF

292 s a stratification tool for future trials of drugs targeting vascular leakage.

293 Ten antiangiogenic drugs targeting VEGF or its receptors are approved for c

294 otherapies that incorporate antiangiogenesis drugs targeting VEGF receptor.

295 Therefore drugs targeting VEGFA/VEGFR-2 are being presently used i

296 ng, we reviewed the development of antiviral drugs targeting viral DNA-packaging motors.

297 will facilitate the development of antiviral drugs targeting viral entry steps but also will lead to

298 This biophysical strategy for drug targeting, which lowers required doses and minimize

299 ontrolled-release drug delivery and improved drug targeting within the eye to increase efficacy and r

300 nd allows the study of novel investigational drugs targeting WM cells in the huBM milieu.